HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 50.3%

Neg 0% Neu 0% Pos 50.3%

HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $12 to $13.